news
Newly discovered mechanism behind cognitive decline in aging
US researchers say new mechanism could lead to new drugs and therapies to treat normal cognitive decline in aging.
List view / Grid view
Dementia
news
Genetic cause of ALS and dementia repaired by RNA-targeting strategy
US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
news
New screening method reveals why Alzheimer’s drugs often fail
Researchers have developed a new method to screen drugs for Alzheimer’s disease, shedding light on why current drugs have failed and identifying novel drug targets.
news
Promising new research could advance memory disorder drug development
Researchers have discovered two types of cells in the brain that are involved in organising discrete memories based on when they occurred. This finding improves the understanding of how the human brain forms memories and could have implications in memory disorders such as Alzheimer’s disease.
news
Scientists ‘reinvent’ petri dish for growing live brain tissue
Researchers have innovated the petri dish to be able to grow and age live brain cells from patients with neurological disorders.
news
Gut-brain pathway metabolite involved in age-related cognitive decline, study shows
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
article
Analysing proteomics data to translate in vivo studies as early as possible
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
news
Measuring microRNAs in blood may indicate dementia risk
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
article
An integrated vaccination approach to neurodegeneration
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
news
Nasal drugs show promise for slowing Parkinson’s disease
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
news
S1P may be a potential target for cerebral blood alterations
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
article
Drug development in stem cell-derived liver organoid models
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
news
Stem cell therapy repairs damage from dementia in mouse brains
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
news
Reduced levels of H2S in rat brains protects against dementia
A study has shown that treatments to reduce levels of hydrogen sulphide (H2S) in the brain may help to prevent dementia.
article
Exploring new drug targets in Alzheimer’s disease
Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.